Hims & Hers Health Inc. (HIMS) stock surged 5.04% in pre-market trading on Monday, riding on the increasing demand for its compound version of Novo Nordisk's popular weight-loss drug Wegovy (semaglutide). The telehealth company's shares have gained momentum as it capitalizes on the shortage of branded obesity drugs by offering cheaper compounded alternatives.
With the obesity drug market heating up, investors are closely watching pharmaceutical giants like Eli Lilly, Novo Nordisk, and Amgen as they compete to develop the next generation of weight-loss medications. However, Hims & Hers has emerged as an unexpected winner by providing compounded versions of existing drugs at a discounted price.
Despite the recent surge, analysts at Leerink Partners have warned that the rally in Hims & Hers shares might not continue in 2025 as the FDA recently removed Lilly's obesity drug Zepbound from the shortage list. This could signal an eventual resolution of the semaglutide shortage, potentially impacting the demand for Hims & Hers' compounded versions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。